VERAXA Biotech Highlights BiTAC Cancer Platforms Ahead of BIO International Convention

VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.

VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.

According to the press release, the BiTAC platforms represent a significant advancement in antibody-based therapeutics. The BiTAC-ADC platform combines bispecific antibodies with antibody-drug conjugates (ADCs) to achieve tumor-restricted activation, potentially reducing systemic toxicity. The BiTAC-TCE platform focuses on bispecific T cell engagers, which recruit T cells to attack cancer cells. Together, these platforms address key challenges in solid tumor treatment, where precise targeting and immune activation are critical.

The company emphasized that the new proof-of-concept data validates the platforms' potential, and they are actively seeking partners to advance development. For more details, the full press release is available at https://ibn.fm/1je4A.

VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

The BIO International Convention is a major industry event where companies showcase their latest innovations and seek collaborations. VERAXA's participation underscores its commitment to advancing cancer therapies and expanding its pipeline through strategic partnerships. The company's stock trades on Nasdaq under the ticker VRXA, and more information can be found in the company's newsroom at http://ibn.fm/VRXA.